- PR Newswire•2 days agoPerrigo Announces FDA Final Approval For Hydrocodone Bitartrate And Homatropine Methylbromide Oral Solution
DUBLIN, Feb. 17, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL. Hydrocodone bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL is indicated for the symptomatic relief of cough in adults and children 6 years of age and older. Perrigo CEO John T. Hendrickson stated, "This final approval is another example of Perrigo's ongoing commitment to developing high quality value alternatives in important treatment categories.
- PR Newswire•5 days ago
DUBLIN, Feb. 14, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release financial results for its fourth quarter and calendar year 2016 on Monday, February 27, ...
- Investopedia•6 days ago
Jeff Smith, the activist investor, has clenched five seats on the drug manufacturer's board of directors and a spot on two different strategic committees.
PRGO : Summary for Perrigo Company plc Ordinary Sh - Yahoo Finance
Perrigo Company plc (PRGO)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||82.54 - 84.64|
|52 Week Range||71.84 - 140.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-8.38|
|Dividend & Yield||0.58 (0.69%)|
|1y Target Est||N/A|